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Abstract
Background: Data on the prevalence of perennial versus seasonal allergic asthma in Italy are lacking; moreover,
there is limited evidence on the effect of omalizumab on patient-reported outcomes in Italian patients with severe
allergic asthma. PROXIMA, an observational, multicenter study, was designed to assess the prevalence of perennial
versus seasonal allergic asthma (cross-sectional phase) and the effect of omalizumab on improving illness perception,
quality of life (QoL) and asthma control of Italian patients with severe allergic asthma (longitudinal phase).
Methods: The study included a cross-sectional phase (n = 357) and a longitudinal phase (n = 123): during the
longitudinal phase, patients received omalizumab (75–600 mg subcutaneously every month) and were followed-up for
12 months. The primary parameter of cross-sectional phase was prevalence of perennial allergic asthma and that of
longitudinal phase was proportion of patients with asthma control (assessed using asthma control questionnaire [ACQ]).
Secondary parameters assessed were patients’ disease perception, level of asthma control, exacerbation rate during both
cross-sectional and longitudinal phases, and patients' compliance to and persistence with omalizumab, and patients' QoL
during the longitudinal phase.
Results: Most patients (95.8%) had perennial allergies; 81% had polysensitization. Of 99 patients in the per-protocol set, 95
(95.96% [95% CI: 89.98–98.89%]) achieved asthma control (ACQ < 4) at both 6 and 12 months of omalizumab treatment;
ACQ score decreased after 6 and 12 months (P < 0.0001). Omalizumab treatment resulted in a significant improvement in
QoL and patients’ illness perception and 87% decrease in exacerbation rate. The compliance rate with omalizumab was
high (73.2%). No new safety signals were identified during treatment.
Conclusion: This study demonstrated that in severe allergic asthma, omalizumab improves patient-reported outcomes
such as patients’ illness perception and QoL, while confirming improvement of asthma control and exacerbation rate
reduction in Italian patients.
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Background
Asthma affects around 334 million people globally and
results in ~ 250,000 deaths every year [1]. In Italy a trend
toward increasing prevalence of asthma was observed be-
tween 1991 and 2010 with a 38% increase in the incidence
rate [2]. According to Global Initiative for Asthma (GINA)
guidelines, severe asthma is a condition requiring GINA
step 4 or 5 treatment (e.g. high-dose inhaled corticoster-
oid/long-acting beta-2 agonist [ICS/LABA]), to prevent it
from becoming uncontrolled, or asthma that remains
uncontrolled despite this treatment [3]. For patients who
remain uncontrolled or poorly controlled despite treat-
ment with ICS/LABA, step-up with add-on anti-IgE has
been recommended [3]. Severe asthma affects ~ 5%–10%
of all patients with asthma and is characterized by poor
asthma control, reduced lung function, impaired quality of
life (QoL), and high risk of exacerbations and mortality [4,
5]. Almost 59%–80% of patients with severe asthma have
an allergic component to their disease; allergic asthma is
typically characterized by immunoglobulin E (IgE)-me-
diated hypersensitivity [6–11]. Sensitization to perennial
allergens such as house-dust mite, pet allergens and fun-
gus, and seasonal allergens such as pollen imposes a high
risk of developing asthma [12]. Exposure to aeroallergens
triggers Th2 cell-mediated immune response resulting in
increased levels of IgE antibodies [13–15], which then bind
to the high-affinity IgE receptors (FcεRI) on the effector
cells such as mast cells and basophils. Subsequently, this
results in the release of various chemical mediators leading
to asthma-related symptoms such as wheezing, coughing,
chest tightness and shortness of breath [16].
Omalizumab, a humanized recombinant monoclonal
anti-IgE antibody, is approved in Europe, as an add-on
therapy (75–600 mg subcutaneously every 2 or 4 weeks)
for management of severe persistent allergic asthma in
patients aged ≥6 years with symptoms inadequately
controlled with high-dose ICS/LABA [17]. Omalizumab
improved asthma control and QoL, with 50% reduction in
severe exacerbation rate in patients with severe allergic
asthma (SAA) [18]. Effectiveness of omalizumab in treating
patients with SAA and improving patient-reported
outcomes (PROs) has also been consistently evidenced in
real-life observational studies from France, Germany,
Belgium, United Kingdom, South-Eastern Mediterranean
centers and Spain [19–24].
Assessment of PROs plays an important role in moni-
toring asthma control and in optimizing the interaction
between the patients and the physicians [25, 26]. Unfor-
tunately, patients’ viewpoint on their disease condition
and treatment efficacy so far has been rather neglected.
However, in the recent days, asthma management strat-
egy moved towards a patient-centric approach reflecting
more on patients’ viewpoint on their disease condition
and treatment approach [27].
To date, no studies have been published on the preva-
lence of SAA in the Italian population; moreover, limited
information is available on the effectiveness of omalizu-
mab in treatment of SAA in Italian real-life settings. The
PROXIMA (Patient Reported Outcomes and Xolair® In
the Management of Asthma) study was designed primar-
ily to assess the prevalence of perennial allergic asthma
in the Italian population during the cross-sectional
phase and to determine the proportion of patients with
SAA treated with omalizumab who achieved and sus-
tained asthma control over 12 months in the longitu-
dinal phase [28]. The secondary objectives included
assessment of patients' disease perception, level of
asthma control, and rate of exacerbations during both
cross-sectional and longitudinal phases of the study, and
patients' compliance to and persistence with omalizu-
mab, and patients' QoL during the longitudinal phase.
Methods
Study design and patients
PROXIMA was an observational, two-phase study con-
ducted from 27th December, 2013 to 21st June, 2016 at 25
outpatient settings in Italy (hospitals and university centers
specialized in asthma treatment) [28]. The study consisted
of a cross-sectional phase and a prospective longitudinal
phase. Patients aged ≥18 years, diagnosed with SAA, who
were at step 4 as per GINA guidelines and required a thera-
peutic step-up, were included in the cross-sectional phase.
Patients who started treatment with omalizumab as per
clinician judgement (according to AIFA criteria) at baseline
visit were included in the longitudinal phase. Patients
started omalizumab treatment not earlier than 15 days
before enrolment, and within 90 days after enrolment and
were followed-up for 12 months.
Patients were excluded if they were unable to complete
the patient questionnaire or were involved in any experi-
mental study during the study entry.
Patients received omalizumab as per clinical practice
[17] and were followed-up for 12 months. The follow-up
visits were scheduled at 6 and 12 months.
The study was conducted in accordance with the eth-
ical principles laid down in the Declaration of Helsinki
and the Italian Medicines Agency (AIFA) Guideline for
classification and management of observational studies
on drugs [29–31]. All patients provided informed con-
sent before participating in the study.
Assessments
The primary objectives were to determine: (i) proportion
of patients with perennial versus seasonal allergic
asthma based on the clinician’s judgment and a skin
prick test or an in vitro test (at baseline, cross-sectional
phase) and (ii) proportion of patients who achieved and
maintained asthma control (at 6 and 12 months) with
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omalizumab (longitudinal phase). Asthma control was eval-
uated using Asthma Control Questionnaire (ACQ), a vali-
dated tool with a 7-point scale (score 0: well-controlled,
score 6: extremely poorly controlled). Patients with an
ACQ score < 4 at both 6 and 12 months after treatment
were considered as “responders”. Patients with an ACQ
score < 4 at either 6 or 12 months were classified as “con-
trolled” patients, and those with an ACQ score < 1 at either
6 or 12 months were classified as “fully controlled” [32].
Secondary objectives for cross-sectional phase included:
level of asthma control, patients’ disease perception (using
Brief Illness Perception Questionnaire [BIPQ, a 9-item
questionnaire]), and exacerbation rate at baseline in the
overall population and in patients with perennial versus
seasonal asthma. Secondary parameters for longitudinal
phase included: proportion of patients with ≥1 episode of
asthma exacerbation during 12-month treatment period;
patients’ disease perception and QoL (using EuroQoL
five-dimensional three-level questionnaire [EQ-5D-3 L])
at 6 and 12 months; patients’ compliance to omalizumab
at 6 and 12 months; and, patients’ persistence with omali-
zumab treatment during 12 months. Safety assessments
included recording of adverse events (AEs).
Statistical analysis
PROXIMA was an observational study with no confirma-
tory aims. Overall, 357 patients and 99 patients, respect-
ively, were evaluable for the primary objective of the
cross-sectional and longitudinal phase. Considering the
sample size of 357 patients for the cross-sectional phase,
the maximum allowable precision of the estimate (i.e. width
of 95 confidence interval [CI]) reached when the proportion
is 50%, is 10.4%. With respect to the longitudinal phase, the
maximum allowable precision of the estimate, considering
99 evaluable patients, is 19.6%; this precision increased to
11.8%, when the proportion is equal to 90% (i.e. that ob-
served in the study). In accordance with the aforemen-
tioned statement, the precision of the estimate was < 15%.
The data on primary parameters were descriptively
summarized, and corresponding 95% CIs were pre-
sented. Wilcoxon nonparametric test was performed to
compare BIPQ domain scores and ACQ total scores be-
tween patients with perennial and seasonal asthma. Fish-
er’s exact test was used for frequency of patients with
good–moderate control (ACQ < 4) or with poor–very
poor control (ACQ ≥4) [32] in patients with perennial
versus seasonal asthma. Paired sample t-test (or non-
parametric signed rank test) was performed to assess
changes in ACQ scores, EuroQoL Visual Analog Scale
(EQ-VAS), and BIPQ domain scores from baseline to 6
and 12 months. Kaplan–Meier survival curve analysis
was performed to evaluate persistence with omalizumab
treatment during the 12-month follow-up period.
The cross-sectional population included all enrolled
patients who met inclusion and exclusion criteria for the
cross-sectional phase; and the longitudinal population
included all patients enrolled in the longitudinal phase
as defined in the key inclusion criteria; and the
per-protocol population included all evaluable patients
who completed the longitudinal phase and for whom
ACQ score at 6 and/or 12 months was computable.
Sensitivity analysis
To evaluate omalizumab effects on asthma control, con-
sidering also patients with missing ACQ total scores at
one of the follow-up visits, the concepts of “worst
scenario” and “best scenario” were adopted. In worst
scenario analysis, patients with missing ACQ total scores
at 6- or 12-month follow-up visits were considered as
“not controlled”. In best scenario analysis, patients with
missing ACQ total scores were considered “controlled”
if ACQ scores were < 4 in any one assessment, and
patients were not dropped out owing to efficacy.
Results
Patient demographics and clinical characteristics
Of 365 patients enrolled, 357 contributed to the
cross-sectional population set, and 123 to the longitudinal
population set (Fig. 1). The majority of patients in both
phases were women (62%–65%) and Caucasians (~ 95%)
with mean asthma duration of ~ 19 years, and had at least
one co-morbidity (> 58%; Table 1). Cardiovascular diseases
were the most frequent comorbidities in both the popula-
tion sets (~ 21%), followed by chronic rhinitis in the
cross-sectional population (~ 15%) and chronic sinusitis/
rhinosinusitis in the longitudinal population. Mean num-
ber of asthma exacerbations during the 12 months before
enrolment was 3.6 in the cross-sectional population and
4.6 in the longitudinal population (Table 1).
Cross-sectional phase
Prevalence of perennial versus seasonal allergic asthma
Based on clinical judgment, 95.8% (n = 342) patients had
perennial allergies (95% CI: 93.2–97.6%), and 4.2% (n =
15) patients had seasonal allergies (95% CI: 2.4–6.8%). A
similar trend was observed based on confirmatory
allergy test: 83.8% (n = 299) patients had perennial aller-
gies and 10.1% (n = 36) patients had seasonal allergies.
The majority of patients (81% [n = 289]) were positive to
more than one allergen (polysensitization). The most
common trigger for perennial asthma, as judged by the
physician, was dermatophagoides (74.3% [n = 248]), and
for seasonal asthma was grasses (60.0% [n = 9]; Table 2).
Patients’ perception of asthma
Perception of illness was comparable between patients
with perennial and seasonal asthma for all BIPQ domains,
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Fig. 1 Patient disposition. *Of 123 patients, 104 completed the longitudinal phase and 19 discontinued, 8 of whom were lost to follow-up, 7
patients voluntarily discontinued the study and 4 patients withdrew for to other reasons. (SAA, severe allergic asthma)





Female 232 (65.0) 76 (61.8)
Caucasian 340 (95.2) 117 (95.1)
Age, years (mean ± SD) 50.5 ± 15.5 52.7 ± 13.6
At least one comorbidity 208 (58.3) 77 (62.6)
Asthma duration, years (mean ± SD)a 18.4 ± 14.9 19.8 ± 14.5
Age at diagnosis, years (mean ± SD)a 32.1 ± 17.4 32.7 ± 15.8
Number of asthma exacerbations during
the 12 months before enrolmentb
3.6 ± 4.2 4.6 ± 4.1
ACQ total scoresc 2.4 ± 1.2 2.9 ± 1.1
Smoking history
Non-smoker 265 (74.2) 90 (73.2)
Former smoker 67 (18.8) 27 (22.0)
Current smoker 25 (7.0) 6 (4.9)
FEV1 (L)
d 2.0 ± 0.8 1.7 ± 0.7
IgE serum level, IU/mL, (mean ± SD)e 434.8 ± 556.4 409.3 ± 394.1
At least one concomitant pharmacological
treatment for respiratory disease
– 122 (99.2)
Corticosteroids for systemic use – 50 (40.7)
Data are presented as n (%), unless otherwise specified
an = 347 in cross-sectional population and n = 119 in longitudinal population
bn = 330 in cross-sectional population and n = 119 in longitudinal population
cn = 339 in cross-sectional population and n = 96 in longitudinal population
dn = 342 in cross-sectional population and n = 121 in longitudinal population (assessed at baseline or within 3 months before enrolment)
en = 252 in cross-sectional population and n = 121 in longitudinal population (assessed at baseline or within 3 months before enrolment)
ACQ asthma control questionnaire, FEV1 forced expiratory volume in one second, IgE immunoglobulin E, SD standard deviation
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except the “timelines” domain (P = 0.0414). These data
suggest that patients with perennial asthma perceive their
duration of illness to be longer than those with seasonal
asthma (Fig. 2), which was to be expected because peren-
nial allergies last year-round.
Asthma control
The majority of patients (89.7% [n = 304]) demonstrated
good–moderate level of asthma control (ACQ < 4), with
a mean ± SD ACQ total score of 2.4 ± 1.2. No significant
difference was observed in ACQ total scores in patients
with perennial and seasonal allergies (mean ± SD: 2.4 ±
1.2 [n = 325] vs. 2.3 ± 1.3 [n = 14]; P = 0.7038).
Asthma exacerbations
The mean ± SD number of asthma exacerbations during
12 months before enrolment was 3.6 ± 4.2 and the propor-
tion of patients with ≥1 asthma exacerbation in the
12 months before baseline visit was 87.6% (n = 289/330).
Exacerbation rates were similar in patients with perennial
and seasonal asthma (3.6 ± 4.2 vs. 3.0 ± 2.3; P = 1.000).
Most patients with perennial (87.5% [n = 279/319]) and
seasonal (90.9% [n = 10/11]) asthma experienced ≥1
exacerbation in the 12 months before baseline visit.
Longitudinal phase
Patients’ perception of asthma
Omalizumab significantly improved most of the compo-
nents of BIPQ questionnaire after 6 and 12 months
(Table 3). Patients reported to have experienced better
asthma control, to have a less severe impact of asthma
on their lives, to have experienced less symptoms from
their illness, and to be less concerned and emotionally
affected by their illness. Overall, patients’ QoL improved
during treatment with omalizumab.
Table 2 Frequency of aeroallergens in ≥20% of patients with perennial and seasonal allergic asthma (according to clinician
judgement) (cross-sectional population)
Allergen Patients with perennial allergens
(N = 342)
Patients with seasonal allergens
(N = 15)
Grasses 174/315 (55.2%) 9/15 (60.0%)
Pellitory 134/319 (42.0%) 4/14 (28.6%)
Birch 67/288 (23.3%) 3/14 (21.4%)
Hazel 46/269 (17.1%) 3/14 (21.4%)
Cypress 66/285 (23.2%) 4/13 (30.8%)
Olive tree 92/311 (29.6%) 3/13 (23.1%)
Dermatophagoides 248/334 (74.3%) 2/14 (14.3%)
Cat epidermal allergen 97/305 (31.8%) 1/14 (7.1%)
Dog epidermal allergen 66/299 (22.1%) 1/14 (7.1%)
Fig. 2 Patients’ illness perception, assessed by BIPQ at baseline (cross-sectional population). *P = 0.041 for perennial vs seasonal asthma patients; p
values are non-significant for the remaining components. P-values were calculated using Wilcoxon test. BIPQ, Brief Illness Perception Questionnaire
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Quality of life
Compared with baseline, a greater proportion of patients re-
ported no problem in mobility, self-care, performing usual
activities, pain/discomfort, and anxiety/depression during 6-
and 12-month follow-up periods, as assessed by Euro-QoL
5D-3 L (Table 4). Moreover, omalizumab significantly im-
proved (P < 0.0001) the QoL, as shown by VAS score
changes at 6 months (+ 13.9 ± 17.4) and at 12 months
(+ 15.4 ± 20.3) compared with baseline, assessed by EQ-VAS.
Proportion of patients with asthma control
Asthma control following omalizumab treatment was
assessed in the per-protocol population (n = 99). Most
patients achieved disease control at 6 months, which was
maintained until 12 months (responders) after omalizu-
mab treatment (best scenario: 95.96%, n = 95/99, 95% CI:
89.98–98.89%; worst scenario: 89.90%, n = 89/99, 95% CI:
82.21–95.05%). Of note, ~ 20–23% of patients achieved
full asthma control (ACQ < 1) at both 6 and 12 months of
treatment (best scenario: 23.23%, n = 23/99, 95% CI:
15.33–32.79%; worst scenario: 20.20%; n = 20/99, 95% CI:
12.80–29.46%; Fig. 3).
Asthma control – ACQ scores
A significant improvement (P < 0.0001) in mean ACQ
total scores and individual domain scores from baseline
was observed at 6 and 12 months (Table 5). Of particu-
lar note, an improvement in lung function, as reflected
by an increase in forced expiratory volume in 1 s (FEV1),
was observed at 6 and 12 months. At baseline, patients
had a mean FEV1 of 1.7 L which increased by 400 mL at
6 months and by 500 mL at 12 months.
Asthma exacerbations
The proportion of patients experiencing ≥1 asthma ex-
acerbation was reduced following omalizumab treatment
during 12 months. Of 121 patients, 33 (27.27%; 95% CI:
19.57–36.12%) experienced ≥1 asthma exacerbation dur-
ing the 12 months following treatment compared with
114 of 119 patients (95.8%) who experienced ≥1 asthma
exacerbation in the 12 months before baseline visit. The
mean ± SD number of exacerbation episodes per patient
reported during the 12 months before enrolment was 4.6
± 4.1 and omalizumab significantly (P < 0.0001) reduced
the rate of exacerbations by 87% to 0.6 ± 1.2 (n = 121) at
12 months, with a total mean ± SD change of − 4.0 ± 4.2
(n = 117) in number of exacerbations from baseline.
Patient compliance to omalizumab and treatment
persistence
A mean ± SD compliance rate of 96.9 ± 7.8% (n = 123) was
observed for omalizumab during 12-month follow-up
Table 3 Illness perception (assessed by BIPQ) following omalizumab treatment at each time point (longitudinal population)
Component Baseline Change at 6 months from baseline P-value Change at 12 months from baseline P-value
Consequences 7.3 ± 1.9 −2.0 ± 2.4 < 0.0001 −2.2 ± 2.7 < 0.0001
Timeline 8.1 ± 2.4 −1.0 ± 2.5 < 0.0001 −0.3 ± 2.4 0.1938
Personal control 5.9 ± 2.0 0.7 ± 2.3 0.0005 0.9 ± 2.5 0.0003
Treatment control 7.2 ± 2.3 0.9 ± 2.6 0.0001 1.1 ± 2.5 < 0.0001
Identity 7.6 ± 1.7 −2.2 ± 2.5 < 0.0001 −2.0 ± 2.6 < 0.0001
Concern 7.4 ± 2.3 −1.6 ± 3.0 < 0.0001 − 1.7 ± 3.0 < 0.0001
Emotions 7.0 ± 2.6 −1.2 ± 2.8 < 0.0001 −1.1 ± 3.0 < 0.0001
Illness comprehensibility 7.1 ± 2.3 0.4 ± 2.3 0.0690 0.7 ± 2.4 0.0076
Data presented as mean ± SD
P < 0.05 is considered as statistically significant. P-value was calculated using Wilcoxon test
BIPQ Brief Illness Perception Questionnaire
Table 4 Patients with improved quality of life – EQ-5D-3 L questionnaire (longitudinal population)




No problems in walking 47.9 73.5 72.8
No problems in self-care 74.4 91.2 90.3
No problems in performing usual activitiesa 36.7 58.4 65.0
No pain/discomfortb 31.4 61.9 63.7
No anxiety/depression 34.7 57.5 57.3
VAS scores, mean ± SD 55.1 ± 18.4 69.2 ± 15.9 71.0 ± 16.0
Data are presented as % of patients, unless otherwise specified
aN = 120 at baseline; bN = 102 at 12 months
P < 0.0001 for VAS score changes from baseline to 6 months as well as 12 months. P-value was calculated using paired t-test
EQ-5D-3 L EuroQoL five-dimensional three-level questionnaire, SD standard deviation, VAS Visual Analogue Scale
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period. The maximum exposure time to omalizumab was
407.0 days. Of note, majority of patients remained in treat-
ment with omalizumab during the whole observation
period: 102 patients (82.9%) during the first 6-month
follow-up period, 96 (88.1%) during the second 6-month
follow-up period, and 90 (73.2%) considering the overall
12 months of follow-up. Only nine (7.3%) patients
reported permanent discontinuation of omalizumab and
four of these patients discontinued due to lack of efficacy.
Safety
Omalizumab was well tolerated during the study and no
new/unexpected AEs were reported. Eighteen (14.6%)
patients reported ≥1 AE; infections and infestations
(5.7%; 7 patients), followed by respiratory, thoracic and
mediastinal disorders (4.1%; 5 patients) occurred more
frequently. Six (4.9%) patients reported drug-related AEs
and four patients had AEs leading to treatment discon-
tinuation. Three (2.4%) patients reported serious AEs
(SAEs) – serious pelvic fracture, pulmonary edema and
serious asthma; one patient (0.8%) discontinued due to
SAE of pulmonary edema.
Discussion
The PROXIMA study evaluated the prevalence of allergy
to perennial and seasonal aeroallergens in Italian patients
with SAA. The study also assessed the level of asthma
control, patients’ illness perception, asthma exacerbations
and QoL in patients with SAA. Of the total enrolled popu-
lation, 123 patients received add-on omalizumab therapy
in the longitudinal phase.
In general, a high degree of polysensitization to multiple
perennial and seasonal allergens was observed in the
A
B
Fig. 3 Percentage of (a) controlled (ACQ < 4) and (b) fully controlled patients (ACQ < 1) in the worst and best scenarios. Best scenario: Patients with
missing ACQ total scores were considered "controlled" if ACQ scores were <4 in any one assessment, and patients were not dropped out owing to
efficacy. Worst scenario: Patients with missing ACQ total scores at 6 or 12 months follow-up visits were considered "not controlled". *Responders were
patients who achieved asthma control (ACQ< 4) at both 6 and 12 months. ACQ, Asthma Control Questionnaire
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Italian population. Dermatophagoides was the most fre-
quent one, accounting for perennial allergies followed by
grasses and pellitory. Seasonal allergies were attributed to
frequent exposure to grasses, cypress and pellitory. These
findings were in line with other studies, which report aller-
gic sensitization to a wide range of allergens in the Italian
population [33–35], contributing to high prevalence of al-
lergic rhinitis, a condition associated with increased risk of
developing asthma.
The novelty of the PROXIMA study comes from the
evaluation of the disease perception and the QoL of pa-
tients by the means of PROs, which have been exploited as
secondary objectives. Indeed PROs have been used only in
20 clinical trials out of ~ 300 in the last 1 year and half, but
none of them was done in a real-life setting – PROXIMA
study assessed these outcomes in real-life scenario [27].
Moreover, the internationally recognized global evalu-
ation of treatment effectiveness (GETE) consider as a
part of the overall assessment, the response to therapy
made by the patient [36]. Thus the patient’s point of
view is increasingly becoming part of the therapy evalu-
ation. From this perspective, PROXIMA is the first study
to consider the patients' disease perception together with
the assessment of the QoL through the EuroQoL 5D-3 L
questionnaire in patients with SAA.
While PROs can provide important insights about the
burden of the disease and the efficacy of the treatment,
sometimes, especially in asthma, improvement of clinical
parameters may not correlate well with the patient ex-
perience [37]. But, here we have shown that the treat-
ment of SAA with omalizumab is able to improve not
only the clinical parameters including ACQ, exacerba-
tion rate and FEV1 but also the PROs.
BIPQ scores reflect patients’ perception on their cog-
nitive and emotional representation of illness [38]. Pa-
tients with either perennial or seasonal asthma reported
to have experienced a discrete number of symptoms
from their illness and were somehow concerned about
their illness. Overall, they expressed their QoL to be
quite affected by their illness, confirming the big impact
that SAA can have on patients. Moreover, the level of
asthma control, the proportion of patients with
good-moderate asthma control and the asthma exacer-
bation rate were similar between patients with perennial
and seasonal allergic asthma. To the best of our know-
ledge, this is the first study to report the effect of omali-
zumab on patients’ illness perception using BIPQ scores.
During the longitudinal phase, treatment with omali-
zumab improved all the items of BIPQ scores resulting
in improved patients’ perception of the disease. Patients
reported better asthma control and improved symptoms,
and were less concerned and emotionally affected by
their illness. Patients’ QoL also improved with omalizu-
mab treatment, as reflected in increased VAS scores and
an increase in the proportion of patients with no prob-
lems in mobility or self-care or in performing usual ac-
tivities, and without pain/discomfort/anxiety/depression,
as assessed by the EQ-5D-3 L. An increase in EQ-VAS
scores after 12 months of omalizumab treatment was
also shown in a pharmaco-epidemiological study in pa-
tients with severe persistent allergic asthma [24]. A simi-
lar trend for improvement in QoL scores was noted in
an observational study (APEX II study) in the UK [22].
In this study, omalizumab demonstrated an 87% decrease
in exacerbation rate from baseline and a significant reduc-
tion in the proportion of patients experiencing ≥1 exacer-
bation over 12 months. Consistently, in a recent Italian
study [39], over 50% of patients had no exacerbations
following omalizumab treatment. The eXpeRience study
showed a reduction in the proportion of patients with clin-
ically significant asthma exacerbations (from 93.2 to 45.9%)
with 2-year omalizumab treatment [40]. A large
Table 5 Summary statistics of asthma control (assessed by ACQ) at each time point (per-protocol population)
Baseline 6 months 12 months Change from baseline to 6 months;
p value
Change from baseline to 12 months;
p value
ACQ total score 2.9 ± 1.1 1.4 ± 1.0 1.6 ± 1.1 −1.5 ± 1.2; P < 0.0001 −1.4 ± 1.1; P < 0.0001
Item 1 2.1 ± 1.6 1.0 ± 1.3 1.1 ± 1.2 −1.1 ± 1.6; P < 0.0001 −1.0 ± 1.7; P < 0.0001
Item 2 3.1 ± 1.7 1.3 ± 1.2 1.5 ± 1.4 −1.8 ± 1.8; P < 0.0001 −1.6 ± 1.9; P < 0.0001
Item 3 3.2 ± 1.4 1.3 ± 1.2 1.5 ± 1.3 −1.9 ± 1.7; P < 0.0001 −1.7 ± 1.7; P < 0.0001
Item 4 3.7 ± 1.6 1.7 ± 1.5 1.8 ± 1.5 −1.9 ± 1.9; P < 0.0001 −1.9 ± 1.8; P < 0.0001
Item 5 3.1 ± 1.8 1.4 ± 1.5 1.6 ± 1.7 −1.7 ± 1.7; P < 0.0001 −1.6 ± 1.9; P < 0.0001
Item 6 1.4 ± 1.2 0.6 ± 1.0 0.6 ± 0.9 −0.8 ± 1.4; P < 0.0001 −0.7 ± 1.2; P < 0.0001
FEV1 pre-bronchodilator (L) 1.7 ± 0.7 2.1 ± 0.9 2.2 ± 1.1 0.4 ± 0.6; P < 0.0001 0.4 ± 0.9; P < 0.0001
Item 7 4.2 ± 1.6 3.0 ± 2.0 3.0 ± 2.0 −1.2 ± 1.8; P < 0.0001 −1.2 ± 2.1; P < 0.0001
Data are presented as mean ± SD
ACQ total score was evaluated using Paired sample t-test; ACQ individual component scores were evaluated using Signed Rank test
P < 0.05 is considered statistically significant
ACQ Asthma Control Questionnaire
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longitudinal study [41], and a systematic review of 24
real-life effectiveness studies of omalizumab [42], have re-
ported remarkably diminished rates of asthma exacerba-
tions with omalizumab treatment. During the
pre-omalizumab period, a high exacerbations rate has been
experienced by the patients associated with poor QoL, and
after omalizumab treatment, a reduction in exacerbation
rate along with an improvement in QoL was observed.
Based on this, it can be hypothesized that significant reduc-
tion in exacerbations may be the major determinant of the
observed improvement in patients’ QoL.
Treatment with omalizumab showed a significant im-
provement in asthma control at 6 and 12 months. These
results were consistent with the data from a real-world glo-
bal study – the eXpeRience study [40], and other similar
real-life studies in Spain and Portugal [3, 20], where omali-
zumab treatment resulted in improved asthma control. In
the PROXIMA study, the proportion of responders (ACQ
< 4) was high with omalizumab treatment, with a response
rate of 89–96%. These data were well supported by results
from the eXpeRience and the XCLUSIVE study [40, 43],
where ~ 70–79% of patients were responders (achieved ex-
cellent/good response as analyzed by GETE) after 4 months
of omalizumab treatment. Importantly, an appreciably high
response rate to omalizumab was obtained despite high co-
morbidities in this population and more severe disease, in-
dicating omalizumab’s effectiveness in SAA patients with
comorbidities. Furthermore, omalizumab also showed sig-
nificant improvement in each item of the ACQ, demon-
strating omalizumab benefits in improving lung function
and reducing night-time awakenings, symptoms, and res-
cue medication use without loss of asthma control.
A high compliance rate (97%) to omalizumab was ob-
served during the 12-month treatment period in the
PROXIMA study with 90 (73.2%) patients persisting with
the treatment (not withdrawing from the study either per-
manently or temporarily); only 9 patients reported perman-
ent discontinuation. These beneficial effects could be
attributed to reduced exacerbation rates and low incidence
of AEs and SAEs observed with omalizumab treatment. In
particular, no cardiovascular/cerebrovascular AEs were re-
ported with omalizumab. This trend was similar to that in a
retrospective study where ~ 65% of patients were compliant
to omalizumab and 54% of omalizumab users were persist-
ent with treatment [44]. Overall, the safety data reported in
this study are concordant with the known safety profile of
omalizumab and the current omalizumab summary of
product characteristics (SmPC)-reported findings [17].
Limitations
The study design used for PROXIMA study may impose a
potential risk of selection bias owing to exclusion of pa-
tients who are unable to complete the patient
questionnaires. However, this choice was necessary to sat-
isfy the study objectives.
Conclusions
In the PROXIMA study, omalizumab significantly
improved illness perception and QoL after 12 months of
treatment. The study revealed a wide-spread trend of
allergy to perennial allergens among SAA patients in Italy.
The study demonstrated the effectiveness of omalizumab in
SAA patients by improving asthma control and decreasing
exacerbation rate. Of note, patient compliance to
omalizumab was high and the effectiveness of omalizumab
was observed in a very severe group of patients.
Abbreviations
ACQ: Asthma Control Questionnaire; AEs: Adverse events; BIPQ: Brief Illness
Perception Questionnaire; CI: Confidence interval; EQ-5D-3 L: EuroQoL five-
dimensional three-level questionnaire; EQ-VAS: EuroQoL Visual Analog Scale;
FEV1: Forced expiratory volume in 1 s; GETE: Global evaluation of treatment
effectiveness; GINA: Global Initiative for Asthma; ICS: Inhaled corticosteroid;
IgE: Immunoglobulin E; LABA: Long-acting beta-2 agonist; PROs: Patient-
reported outcomes; QoL: Quality of life; SAA: Severe allergic asthma;
SAEs: Serious adverse events; SD: Standard deviation; SmPC: Summary of
product characteristics; VAS: Visual Analog Scale
Acknowledgements
The authors thank Phani Tejasvi Dantu and Ananya Chikramane of Novartis
for providing professional medical writing support, which was funded by
Novartis Pharma AG in accordance with Good Publication Practice (GPP3)
guidelines.
Funding
The study and this work were sponsored by Novartis Farma S.p.A., Origgio
(VA), Italy.
Availability of data and materials
Raw data of PROXIMA study are not available for public disclosure.
Authors’ contributions
GWC and LR conceived the study, participated in its design and analysis
plan. MB participated in the study design and analysis plan. GWC, PR, CB,
MCZ, GM, BM, CC, PS and all the PROXIMA study centers participated in the
data collection process. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was conducted in accordance with the ethical principles laid
down in the Declaration of Helsinki and the AIFA Guideline for classification
and management of observational studies on drugs. All patients provided




Giorgio Walter Canonica reports having received research grants as well as
lecture or advisory board fees from A. Menarini, AstraZeneca, Boehringer
Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline,
Mundipharma, Novartis, Sanofi-Aventis, Teva. Paola Rottoli reports receiving
personal fees and other from Roche, personal fees from Boehringer Ingelheim,
grants and personal fees from Novartis, personal fees from TEVA, other from
Menarini, from null, outside the submitted work. Bruno Macciocchi reports
receiving grants from Boehringer Ingelheim. Pierachille Santus reports receiving
personal fees from Astra Zeneca, grants and personal fees from Boehringer
ingelheim, grants from Almirall, grants and personal fees from Chiesi Farmaceu-
tici, personal fees from Guidotti, personal fees from GSK, personal fees from
Zambon Italia, outside the submitted work. Marta Bartezaghi and Laura Rigoni
are the employees of Novartis.
Canonica et al. World Allergy Organization Journal             Page 9 of 11
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Biomedical Sciences, Personalised Medicine Clinic Asthma &
Allergy, Humanitas University, IRCCS Humanitas Research Hospital, Rozzano,
Milan, Italy. 2Respiratory Diseases and Lung Transplantation Unit, Department
of Medical, Surgical and Neuro Sciences, University of Siena, Siena, Italy.
3Pneumology Unit, AOU Molinette, Department of Medical Sciences,
University of Turin, Turin, Italy. 4Division of Lung Disease, Sandro Pertini
Hospital, Rome, Italy. 5Pneumology Unit, Habilita San Marco, Bergamo, Italy.
6Pneumology Unit, Hospital St. Scholastica, Cassino, Italy. 7Allergy Unit,
Fondazione Policlinico Gemelli, Presidio Columbus, Rome, Italy. 8Division of
Respiratory Diseases, “L.Sacco” University Hospital, ASST
Fatebenefratelli-Sacco, Department of Biological and Clinical Sciences (DIBIC),
University of Milan, Milan, Italy. 9Novartis Farma SpA, Largo U. Boccioni 1,
21040 Origgio, VA, Italy.
Received: 7 June 2018 Accepted: 9 October 2018
References
1. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An
official American Thoracic Society/European Respiratory Society statement:
asthma control and exacerbations: standardizing endpoints for clinical asthma
trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99.
2. de Marco R, Cappa V, Accordini S, Rava M, Antonicelli L, Bortolami O, et al.
Trends in the prevalence of asthma and allergic rhinitis in Italy between
1991 and 2010. Eur Respir J. 2012;39(4):883–92.
3. Pereira Barbosa M, Bugalho de Almeida A, Pereira C, Chen CW, Georgiou P, Peachey
G, et al. Real-life efficacy and safety of omalizumab in Portuguese patients with
persistent uncontrolled asthma. Rev Port Pneumol (2006). 2015;21(3):151–6.
4. Hedlin G, van Hage M. Severe asthma and allergy: mechanisms, diagnostics
and treatment. J Intern Med. 2012;272(2):104–7.
5. Hossny E, Caraballo L, Casale T, El-Gamal Y, Rosenwasser L. Severe asthma
and quality of life. World Allergy Organ J. 2017;10(1):28.
6. D'Amato G, Stanziola A, Sanduzzi A, Liccardi G, Salzillo A, Vitale C, et al.
Treating severe allergic asthma with anti-IgE monoclonal antibody
(omalizumab): a review. Multidiscip Respir Med. 2014;9(1):23.
7. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al.
Clinical and inflammatory characteristics of the European U-BIOPRED adult
severe asthma cohort. Eur Respir J. 2015;46(5):1308–21.
8. The ENFUMOSA and Study Group. The ENFUMOSA cross-sectional European
multicentre study of the clinical phenotype of chronic severe asthma.
European Network for Understanding Mechanisms of Severe Asthma. Eur
Respir J. 2003;22:470–7.
9. Haselkorn T, Borish L, Miller DP, Weiss ST, Wong DA. High prevalence of skin test
positivity in severe or difficult-to-treat asthma. J Asthma. 2006;43(10):745–52.
10. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification
of asthma phenotypes using cluster analysis in the severe asthma research
program. Am J Respir Crit Care Med. 2010;181(4):315–23.
11. Lombardi C, Savi E, Ridolo E, Passalacqua G, Canonica GW. Is allergic
sensitization relevant in severe asthma? Which allergens may be culprit?
World Allergy Organ J. 2017;10(1):2.
12. Baxi SN, Phipatanakul W. The role of allergen exposure and avoidance in
asthma. Adolesc Med State Art Rev. 2010;21(1):57–71 viii-ix.
13. Deo SS, Mistry KJ, Kakade AM, Niphadkar PV. Role played by Th2 type
cytokines in IgE mediated allergy and asthma. Lung India. 2010;27(2):66–71.
14. Maggi E. T-cell responses induced by allergen-specific immunotherapy. Clin
Exp Immunol. 2010;161(1):10–8.
15. Pelaia G, Canonica GW, Matucci A, Paolini R, Triggiani M, Paggiaro P.
Targeted therapy in severe asthma today: focus on immunoglobulin E.
Dovepress. 2017;2017:1979–87.
16. Price D. The use of omalizumab in asthma. Prim Care Respir J. 2008;17(2):62–72.
17. Xolair Summary of Product Characteristics. Date last updated: June 22, 2015.
Date last accessed: 19 June 2017.
18. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits
of omalizumab as add-on therapy in patients with severe persistent asthma
who are inadequately controlled despite best available therapy (GINA 2002
step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16.
19. Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T,
et al. Long-term omalizumab treatment in severe allergic asthma: the
south-eastern Mediterranean “real-life” experience. Pulm Pharmacol Ther.
2012;25(1):77–82.
20. Vennera Mdel C, Perez De Llano L, Bardagi S, Ausin P, Sanjuas C, Gonzalez
H, et al. Omalizumab therapy in severe asthma: experience from the
Spanish registry--some new approaches. J Asthma. 2012;49(4):416–22.
21. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in
patients with severe persistent allergic asthma in a real-life setting in
Germany. Respir Med. 2009;103(11):1725–31.
22. Niven RM, Saralaya D, Chaudhuri R, Masoli M, Clifton I, Mansur AH, et al. Impact of
omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK
multicentre observational study (the APEX II study). BMJ Open. 2016;6(8):e011857.
23. Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, et al.
Omalizumab reduces oral corticosteroid use in patients with severe allergic
asthma: real-life data. Respir Med. 2010;104(9):1381–5.
24. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al.
“Real-life” effectiveness of omalizumab in patients with severe persistent
allergic asthma: the PERSIST study. Respir Med. 2009;103(11):1633–42.
25. Kocks JWH, Seys SF, van Duin TS, Diamant Z, Tsiligianni IG. Assessing
patient-reported outcomes in asthma and COPD patients: which can be
recommended in clinical practice? Curr Opin Pulm Med. 2018;24(1):18–23.
26. O'Connor RD. Treatment with budesonide/formoterol pressurized metered-
dose inhaler in patients with asthma: a focus on patient-reported outcomes.
Patient Relat Outcome Meas. 2011;2:41–55.
27. Braido F, Baiardini I, Canonica GW. Patient-reported outcomes in asthma
clinical trials. Curr Opin Pulm Med. 2018;24(1):70–7.
28. Canonica GW, Bartezaghi M, Marino R, Rigoni L. Prevalence of perennial
severe allergic asthma in Italy and effectiveness of omalizumab in its
management: PROXIMA - an observational, 2 phase, patient reported
outcomes study. Clin Mol Allergy. 2015;13(1):10.
29. AIFA Guideline for the classification and management of observational
studies on drugs (determination march 20, 2008). Available at http://www.
agenziafarmaco.com/en.
30. ISPE. Guidelines for good pharmacoepidemiology practices (GPP).
Pharmacoepidemiol Drug Saf. 2008;17:200–8.
31. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke
JP, et al. The strengthening the reporting of observational studies in
epidemiology (STROBE) statement: guidelines for reporting observational
studies. J Clin Epidemiol. 2008;61(4):344–9.
32. van den Nieuwenhof L, Schermer T, Eysink P, Halet E, van Weel C, Bindels P,
et al. Can the asthma control questionnaire be used to differentiate
between patients with controlled and uncontrolled asthma symptoms? A
pilot study. Fam Pract. 2006;23(6):674–81.
33. Ciprandi G, Cadario G, Di Gioacchino M, Gangemi S, Minelli M, Ridolo E, et
al. Sublingual immunotherapy in polysensitized allergic patients with rhinitis
and/or asthma: allergist choices and treatment efficacy. J Biol Regul
Homeost Agents. 2009;23(3):165–71.
34. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Passalacqua G, Pallestrini E, et al.
Seasonal and perennial allergic rhinitis: is this classification adherent to real
life? Allergy. 2005;60(7):882–7.
35. Olivieri M, Verlato G, Corsico A, Lo Cascio V, Bugiani M, Marinoni A, et al.
Prevalence and features of allergic rhinitis in Italy. Allergy. 2002;57(7):600–6.
36. Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al.
Persistency of response to omalizumab therapy in severe allergic (IgE-
mediated) asthma. Allergy. 2011;66(5):671–8.
37. Corren J, Kavati A, Ortiz B, Vegesna A, Colby JA, Ruiz K, et al. Patient-
reported outcomes in moderate-to-severe allergic asthmatics treated with
omalizumab: a systematic literature review of randomized controlled trials.
Curr Med Res Opin. 2018;34(1):65–80.
38. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception
questionnaire. J Psychosom Res. 2006;60(6):631–7.
39. Novelli F, Latorre M, Vergura L, Caiaffa MF, Camiciottoli G, Guarnieri G, et al.
Asthma control in severe asthmatics under treatment with omalizumab: a
cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015;31:
123–9.
40. Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The
eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic
asthma. Respir Med. 2013;107(8):1141–51.
41. Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, et
al. Does omalizumab make a difference to the real-life treatment of asthma
Canonica et al. World Allergy Organization Journal             Page 10 of 11
exacerbations?: results from a large cohort of patients with severe
uncontrolled asthma. Chest. 2013;143(2):398–405.
42. Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real-life’
effectiveness studies of omalizumab in adult patients with severe allergic
asthma: systematic review. Allergy. 2016;71(5):593–610.
43. Schumann C, Kropf C, Wibmer T, Rudiger S, Stoiber KM, Thielen A, et al.
Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir
J. 2012;6(4):215–27.
44. Broder MS, Chang EY, Ory C, Kamath T, Sapra S. Adherence and persistence
with omalizumab and fluticasone/salmeterol within a managed care
population. Allergy Asthma Proc. 2009;30(2):148–57.
Canonica et al. World Allergy Organization Journal             Page 11 of 11
